Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648]

• Jonathan Oh,
• Minal Barve,
• Neil Senzer,
• Phylicia Aaron,
• Luisa Manning,
• Gladice Wallraven,
• Ernest Bognar,
• Laura Stanbery,
• Staci Horvath,
• Meghan Manley,
• John Nemunaitis,
• Adam Walter,
• Rodney P. Rocconi

Affiliations

Jonathan Oh

Texas Oncology, P.A., Dallas, TX, United States

Minal Barve

Texas Oncology, P.A., Dallas, TX, United States; Mary Crowley Cancer Research Centers, Dallas, TX, United States

Neil Senzer

Gradalis, Inc., Carrolton, TX, United States

Phylicia Aaron

Gradalis, Inc., Carrolton, TX, United States

Luisa Manning

Gradalis, Inc., Carrolton, TX, United States

Gladice Wallraven

Gradalis, Inc., Carrolton, TX, United States

Ernest Bognar

Gradalis, Inc., Carrolton, TX, United States

Laura Stanbery

Gradalis, Inc., Carrolton, TX, United States

Staci Horvath

Gradalis, Inc., Carrolton, TX, United States

Meghan Manley

Gradalis, Inc., Carrolton, TX, United States

John Nemunaitis

Corresponding author.; Gradalis, Inc., Carrolton, TX, United States

Adam Walter

ProMedica, Toledo, OH, United States

Rodney P. Rocconi

University of South Alabama – Mitchell Cancer Institute, Mobile, AL, United States